Vimseltinib may be promising in treating symptomatic tenosynovial giant cell tumour
1. Tumor response rate at 25 weeks was significantly greater in vimseltinib than placebo. 2. Most adverse events were mild-to-moderate ...
Tag: Vimseltinib
#VisualAbstract: Vimseltinib Produces Objective Radiological Responses in Tenosynovial Giant Cell Tumour Patients
Click here to read this study in Lancet. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...